Moderna, Inc.

Informe acción NasdaqGS:MRNA

Capitalización de mercado: US$14.3b

Salud financiera de hoja de balance de Moderna

Salud financiera controles de criterios 6/6

Moderna tiene un patrimonio de los accionistas total de $11.9B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $15.8B y $3.9B respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$6.87b
PatrimonioUS$11.93b
Total pasivoUS$3.88b
Activos totalesUS$15.80b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Oct 11
The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18
Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03
Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Jul 30

Moderna: Really Strong Competition

Jun 30

Moment Of Truth Approaches For Moderna's RSV Vaccine

Jun 18

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Jun 06
What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

May 23

Moderna Q1: A Promising Pipeline Is Undervalued

May 15

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Moderna: Counting On Pipeline Too Much

Feb 23

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($9.7B) de MRNA superan a sus pasivos a corto plazo ($2.2B).

Pasivo a largo plazo: Los activos a corto plazo de MRNA ($9.7B) superan a sus pasivos a largo plazo ($1.7B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: MRNA está libre de deudas.

Reducción de la deuda: MRNA no tenía deudas hace 5 años.

Cobertura de la deuda: MRNA no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: MRNA no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.


Hoja de balance


Descubre empresas con salud financiera